DelveInsight's analysts estimate that the psoriasis market
is poised to show significant growth, mainly attributed to
increasing prevalence, recent drug approvals, and anticipated
launch of novel therapies during the forecast period
(2024–2034).
LAS
VEGAS, June 24, 2024 /PRNewswire/ --
DelveInsight's Psoriasis Market Insights report
includes a comprehensive understanding of current treatment
practices, psoriasis emerging drugs, market share of individual
therapies, and current and forecasted market size from 2020 to
2034, segmented into 7MM [the United
States, the EU4 (Germany,
France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Psoriasis Market Report
- As per DelveInsight analysis, the psoriasis market size in
the US was USD 17 billion in
2022.
- In 2022, the total diagnosed prevalent cases of psoriasis in
the US were ~8 million, projected to increase during the
forecast period (2024–2034).
- Leading psoriasis companies such as AnaptysBio, Nimbus
Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb,
Amgen, Dermavant Sciences, Inc., Janssen Research &
Development, LLC, Sun Pharmaceutical Industries Limited, UCB
Pharma, ACELYRIN Inc., Novartis, and others are developing
novel psoriasis drugs that can be available in the psoriasis market
in the upcoming years.
- The psoriasis therapies in the pipeline include
Imsidolimab, TAK-279, Sonelokimab, BMS-986165, Apremilast,
Tapinarof, JNJ-77242113, Tildrakizumab, Certolizumab pegol,
Izokibep, AIN457, and others.
- In October 2023, the FDA
approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate
to severe psoriasis in adults who are candidates for systemic
therapy or phototherapy. It is the first and only IL-17A and IL-17F
inhibitor approved for the treatment of adults with moderate to
severe plaque psoriasis.
- In October 2023,
Arcutis Biotherapeutics announced the FDA had approved the
supplemental new drug application (sNDA) to expand the indication
of ZORYVE (roflumilast) cream 0.3% for the topical treatment of
plaque psoriasis, including intertriginous areas, to children ages
6 to 11 years.
Discover which therapies are expected to grab major
psoriasis market share @ Psoriasis Market Report
Psoriasis Overview
Psoriasis is a chronic autoimmune skin condition characterized
by the rapid growth of skin cells, leading to the formation of
thick, red, scaly patches that can be itchy and sometimes painful.
These patches, often referred to as plaques, commonly appear on the
elbows, knees, scalp, and lower back but can affect any part of the
body. The exact cause of psoriasis is not fully understood, but it
is believed to result from a combination of genetic predisposition
and environmental factors. The immune system mistakenly attacks
healthy skin cells, accelerating their production and causing the
buildup of plaques. Symptoms of psoriasis vary in severity and can
include red patches of skin covered with silvery scales, dry and
cracked skin that may bleed, itching, burning, or soreness,
thickened or ridged nails, and swollen and stiff joints,
particularly in psoriatic arthritis. Diagnosis typically involves a
physical examination of the affected skin, and in some cases, a
biopsy may be performed to rule out other skin disorders. Treatment
options aim to manage symptoms and may include topical treatments,
phototherapy, systemic medications, and lifestyle modifications to
reduce flare-ups.
Psoriasis Epidemiology Segmentation
According to DelveInsight's analyst, the diagnosed prevalent
cases of Psoriasis are on the rise, and as per the estimates,
the United States accounted for
~61% and ~66% of cases for adults (<19 years) and
children (5–19 years), respectively, in 2023.
The psoriasis market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Diagnosed Prevalent Cases of Psoriasis
- Age-Specific Cases of Psoriasis
- Type-specific Cases of Psoriasis
- Location-specific Cases of Psoriasis
- Severity-specific Cases of Psoriasis
- Treated Cases of Psoriasis in Moderate to Severe Patients
Psoriasis Treatment Market
A variety of agents are available for managing the symptoms of
psoriasis. Patients with mild-to-moderate psoriasis typically use
topical treatments that influence gene transcription, inhibit cell
proliferation, and encourage keratinocyte differentiation. These
treatments often include glucocorticoids, vitamin D analogs, and
phototherapy. Common topical medications are corticosteroids,
retinoids like tazarotene, calcineurin inhibitors such as
tacrolimus, vitamin D analogs like calcipotriene or calcitriol, and
combinations like calcipotriol with betamethasone dipropionate.
Biologics have become highly effective options for patients who
do not respond adequately to traditional systemic therapies, cannot
tolerate them due to side effects, or cannot use them due to other
health conditions.
The psoriasis market is primarily controlled by TNF inhibitors,
interleukin inhibitors, and vitamin D analogs. Additionally, it is
propelled by the rising use of biologic therapies, a growing focus
on precision medicine, and the expansion of topical treatment
choices. The introduction of oral TYK2 inhibitors and nonsteroidal
topical agents has further expanded the range of psoriasis
treatments, enhancing market competitiveness.
Several biosimilars are approved for treating psoriasis and
psoriatic arthritis. AMJEVITA (adalimumab-atto), ABRILADA
(adalimumab-afzb), CYLTEZO (adalimumab-adbm), HADLIMA
(adalimumab-bwwd), HULIO (adalimumab-fkjp), and HYRIMOZ
(adalimumab-adaz) are biosimilars to HUMIRA
(adalimumab). ERELZI (etanercept-szzs) and ETICOVO
(etanercept-ykro) are biosimilars to ENBREL
(etanercept). AVSOLA (infliximab-axxq), INFLECTRA
(infliximab-dyyb), IXIFI (infliximab-qbtx), and RENFLEXIS
(infliximab-abda) are biosimilars to REMICADE
(infliximab).
Learn more about the FDA-approved psoriasis drugs @
Drugs for Psoriasis Treatment
Psoriasis Pipeline Therapies and Key Companies
Psoriasis pipeline possesses some drugs in mid and late-stage
developments to be approved shortly. The emerging landscape holds a
diverse range of therapeutic alternatives for treatment, including
Imsidolimab (AnaptysBio), TAK-279 (Nimbus Lakshmi/Takeda),
Sonelokimab (MoonLake Immunotherapeutics), and others in
different lines of treatment. The expected launch of these
therapies shall further create a positive impact on the market.
Imsidolimab, formerly known as ANB019, is an antibody
designed to inhibit the interleukin-36-receptor (IL-36R).
AnaptysBio is developing it as a potential first-in-class treatment
for generalized pustular psoriasis (GPP). The company has completed
Phase I, II, and III trials, and the results showed that
imsidolimab was generally well-tolerated, with most adverse events
being mild to moderate and resolving without any lasting effects.
In July 2020, the FDA granted
orphan drug designation (ODD) to imsidolimab for treating
GPP. AnaptysBio plans to out-license imsidolimab in 2024 and
present the data at a medical meeting in the second half of
2024.
TAK-279 is a highly selective, oral allosteric
tyrosine kinase 2 inhibitor with the potential to become a leading
treatment for psoriasis and other immune-mediated inflammatory
diseases by targeting the non-receptor tyrosine-protein kinase. It
is currently in Phase III clinical development for psoriasis
treatment. In February 2023, Nimbus
Therapeutics announced the completion of Takeda's acquisition of
Nimbus Lakshmi and its tyrosine kinase 2 (TYK2) inhibitor program,
which includes the oral, selective allosteric TYK2 inhibitor
NDI-034858, now known as TAK-279.
The other late-stage therapies for psoriasis treatment in
development include:
- Imsidolimab: AnaptysBio)
- TAK-279: Nimbus Lakshmi/Takeda
- Sonelokimab: MoonLake Immunotherapeutics
- BMS-986165: Bristol-Myers Squibb
- Apremilast: Amgen
- Tapinarof: Dermavant Sciences, Inc.
- JNJ-77242113: Janssen Research & Development, LLC
- Tildrakizumab: Sun Pharmaceutical Industries Limited
- Certolizumab pegol: UCB Pharma
- Izokibep: ACELYRIN Inc.
- AIN457: Novartis
The anticipated launch of these emerging therapies for psoriasis
are poised to transform the market landscape in the coming years.
As these cutting-edge therapies continue to mature and gain
regulatory approval, they are expected to reshape the psoriasis
market landscape, offering new standards of care and unlocking
opportunities for medical innovation and economic growth.
Discover more about drugs for psoriasis in development @
Psoriasis Clinical Trials
Psoriasis Market Dynamics
The dynamics of the psoriasis market are expected to change in
the coming years. An enriched investment in spreading disease
awareness, direct-to-consumer advertisement, and other
private/government initiatives would increase the probability of
opting for treatment and compliance, hence the market will grow
during our forecast period. The increasingly prevalent pool of
psoriasis could be seen as an expansion of the potential
market, making it an attractive therapy area to invest
in.
There lies tremendous potential in the psoriasis
landscape for drugs with better clinical profiles, especially
in terms of safety. Safety concerns associated with JAK
inhibitors present a significant opportunity for pharmaceutical
companies to improve the safety profile of upcoming drugs.
Additionally, the limited treatment options available for
the relapsed or refractory pool provide lucrative opportunities in
the psoriasis therapeutic space.
As many potential therapies are being investigated for the
treatment of psoriasis, it is safe to predict that the treatment
space will significantly impact the psoriasis market during
the forecast period. Moreover, the anticipated introduction of
emerging therapies with improved efficacy and a further
improvement in the diagnosis rate are expected to drive the
growth of the psoriasis market in the 7MM.
However several factors may impede the growth of the psoriasis
market. Patients with psoriasis confront significant challenges due
to a lack of curative therapeutic choices. Anti-TNF agents,
believed to be one of the most effective medication types, are
associated with the development of immunogenicity and
significant side effects. Psoriasis is accompanied by highly
fatal complications and comorbidities like extraintestinal
manifestations (EIMs), toxic megacolon, and colitis-associated
colorectal cancer (CACC), which require additional medications and
treatments, complicating the psoriasis management process and
leading to increased costs. Furthermore, intensified
competition in the psoriasis market due to numerous emerging
therapies will make the market overcrowded.
Moreover, psoriasis treatment poses a significant
economic burden and disrupts patients' overall well-being and
QOL. Furthermore, the psoriasis market growth may be offset by
failures and discontinuation of emerging therapies,
unaffordable pricing, market access and reimbursement
issues, and a shortage of healthcare specialists. In
addition, the undiagnosed, unreported cases and the
unawareness about the disease may also impact the psoriasis
market growth.
Report
Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [The United States,
the EU-4 (Germany, France, Italy, and Spain), the United Kingdom,
and Japan]
|
Psoriasis Market Size
in the US in 2022
|
USD 17
Billion
|
Key Psoriasis
Companies
|
AnaptysBio, Nimbus
Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb,
Amgen, Dermavant Sciences, Inc., Janssen Research &
Development, LLC, Sun Pharmaceutical Industries Limited, UCB
Pharma, ACELYRIN Inc., Novartis, and others
|
Key Psoriasis Therapies
|
Imsidolimab, TAK-279,
Sonelokimab, BMS-986165, Apremilast, Tapinarof, JNJ-77242113,
Tildrakizumab, Certolizumab pegol, Izokibep, AIN457, and
others
|
Scope of the Psoriasis Market
Report
- Therapeutic Assessment: Psoriasis current marketed
and emerging therapies
- Psoriasis Market Dynamics: Attribute
Analysis of Emerging Psoriasis Drugs
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's Views, Analyst's Views, Psoriasis Market
Access and Reimbursement
To know more about psoriasis treatment options, visit @ New
Treatment for Psoriasis
Table of Contents
1.
|
Psoriasis Market
Key Insights
|
2.
|
Psoriasis Market
Report Introduction
|
3.
|
Psoriasis Market
Overview at a Glance
|
4.
|
Psoriasis Market
Executive Summary
|
5.
|
Disease Background and
Overview
|
6.
|
Psoriasis
Treatment and Management
|
7.
|
Psoriasis
Epidemiology and Patient
Population
|
8.
|
Patient
Journey
|
9.
|
Psoriasis Marketed
Drugs
|
10.
|
Psoriasis
Emerging Drugs
|
11.
|
7 Major
Psoriasis Market Analysis
|
12.
|
Psoriasis
Market Outlook
|
13.
|
Potential of Current
and Emerging Therapies
|
14.
|
KOL Views
|
15.
|
Psoriasis
Market Drivers
|
16.
|
Psoriasis
Market Barriers
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Psoriasis Epidemiology Forecast
Psoriasis Epidemiology Forecast – 2032 report
delivers an in-depth understanding of the disease, historical and
forecasted psoriasis epidemiology in the 7MM, i.e.,
the United States, EU5
(Germany, Spain, Italy,
France, and the United Kingdom), and Japan.
Psoriasis Pipeline
Psoriasis Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key psoriasis companies, including Mylan,
Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences,
Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis
Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin
Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo
Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics,
MetrioPharm, Sienna Biopharmaceuticals, among others.
Plaque Psoriasis Market
Plaque Psoriasis Market Insights, Epidemiology, and Market
Forecast – 2032 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key plaque
psoriasis companies including Suzhou Zelgen Biopharmaceuticals,
Sun Pharmaceutical Industries Limited, GC Cell Corporation,
among others.
Chronic Plaque Psoriasis Pipeline
Chronic Plaque Psoriasis Pipeline Insight
– 2024 report provides comprehensive insights
about the pipeline landscape, pipeline drug profiles, including
clinical and non-clinical stage products, and the
key chronic plaque psoriasis companies, including
Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen
Biopharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/psoriasis-market-to-register-incremental-growth-by-2034-predicts-delveinsight--key-companies---anaptysbio-nimbus-lakshmi-takeda-moonlake-immunotherapeutics-bristol-myers-squibb-amgen-dermavant-sciences-302179978.html
SOURCE DelveInsight Business Research, LLP